AstraZeneca Plc (AZN) announced Tuesday that it's voluntarily delisting its American Depositary Shares and certain guaranteed debt securities from Nasdaq as part of a broader shift to direct stock trading on the New York Stock Exchange.
The transition happens at the end of January 2026. After the market closes on January 30, AstraZeneca's ordinary shares and the affected debt securities will officially move to the NYSE, with trading expected to kick off on February 2. The Nasdaq listings will cease the same day the NYSE trading begins.
This isn't just administrative housekeeping. AstraZeneca is executing a shareholder-approved strategy to simplify its listing structure into what the company calls "a single global framework." Translation: instead of navigating the complexity of American Depositary Receipts, investors will be able to trade the same ordinary shares whether they're in London, Stockholm, or New York.
Once the change takes effect, AstraZeneca ordinary shares will trade across three major exchanges—the London Stock Exchange, Nasdaq Stockholm, and the NYSE. The idea is to make the stock more accessible and attractive to a wider range of global investors.
Michel Demaré, AstraZeneca's Chair, explained the rationale back in September 2025: "Enabling a global listing structure will allow us to reach a broader mix of global investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca's exciting future."











